金吾财讯 | 礼来(LLY)首席执行官大卫·里克斯(DavidRicks)周一透露，公司预估其试验性口服减肥药最早明年年初有望获批。今年年中，礼来将公布口服药orforglipron关键的后期试验数据。当下，礼来正全力推动这款药丸进入市场，旨在与诺和诺德(NVO.US)以及其他规模较小的竞争对手，争夺蓬勃发展的减肥药市场的主要份额。在这一领域，礼来的Zepbond和诺和诺德的Wegovy占据主导地位，不过，礼来及其竞争对手始终在努力研发这些药物的改进版本。与现有的注射剂型相比，口服药服用起来对患者更为便捷。而且，在礼来和诺和诺德难以生产出足够药物以满足激增需求的当下，口服药的生产也更为容易。礼来方面表示，在中期试验中，orforglipron助力患者减轻了14.7%的体重，而服用安慰剂的患者仅减轻了2.3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.